Led · Series C · Jul 2026

Cyllene Therapeutics (formerly EG 427) develops targeted neurotherapeutics using its proprietary HERMES non-replicating HSV-1 vector platform. Its lead candidate, EG110A, is a DNA medicine being developed for multiple severe bladder diseases, including neurogenic detrusor overactivity (NDO) related to spinal cord injury. Ongoing studies have shown substantial and sustained reductions in urinary incontinence episodes for at least nine months post-treatment in patients with spinal cord injury–related NDO. The company plans a Phase 2b/3 study of EG110A in 2027 and intends to expand into overactive bladder and other neurological indications such as pain and migraine. Cyllene recently completed a €33 million Series C financing to fund these clinical and platform-expansion efforts. The company highlights its position as a leader in non-replicating HSV-1 vector technology in neurology.

Participated · Series C · Jun 2026

Flare Therapeutics is a clinical-stage biotech headquartered in Cambridge, Mass., that focuses exclusively on drugging transcription factors using an integrated discovery platform to identify ligands to previously undrugged proteins. The company has prioritized FX-111, a first-in-class degrader targeting ARON for prostate cancer, which received IND clearance and is expected to enter clinical development in Q3 2026. FlareTx is also advancing an ARON RIPTAC program through preclinical development to complement FX-111 and expand its ability to address AR-driven prostate cancer. Separately, FX-909, an oral PPARG inhibitor targeting luminal lineage biology in urothelial cancer, is in a Phase 1B dose expansion and the company intends to progress it via an external partnership. The recent $85M Series C provides capital to advance these programs, support working capital and general corporate purposes. The company appointed Anna Protopapas as CEO concurrent with the financing to guide its next phase of clinical and corporate development.

Led · Series A · Jun 2026

Rapalogix Health develops a TORC1-targeting platform aimed at restoring youthful cellular function in skin and is building both a prescription therapeutics pipeline and professional skincare products. Its lead molecule, RLX-201, is a patented pro-longevity compound and powers the Re-Q Pro-Longevity Face Serum, which launched nationally on May 14, 2026 and is available at dermatology and aesthetic practices across the United States. The company is advancing RLX-202 as its next prescription therapeutic and is using Series A proceeds to fund IND-enabling studies for that candidate. Rapalogix plans to use capital from the financing to expand Re-Q Health nationally. The company has received multiple industry recognitions in 2026, including awards at IMCAS, Octane’s Aesthetics Tech Forum, INNOCOS, and AMWC. The business is led by Co-Founder and CEO Rahul Mehta, PhD.

Participated · Series A · Apr 2026

Stipple Bio leverages its Pointillist Platform to discover tumor-specific cell surface epitopes and develop precision oncology medicines designed to minimize on-target/off-tumor toxicity. Its lead candidate, STP-100, is a novel antibody-drug conjugate (ADC) incorporating tumor-specific binders and is expected to enter clinical studies in early 2027. The company plans to use its Series A proceeds to advance STP-100 into multiple early-stage clinical trials and to expand its pipeline by identifying additional high therapeutic-index targets. Stipple Bio was founded in 2022 by Dr. Aaron Ring and Dr. Aashish Manglik and is led by CEO Jeff Landau. The company recently added Derek DiRocco, PhD and Thilo Schroeder, PhD to its board and retains board members including Vineeta Agarwala and Greg Verdine. Stipple Bio raised $100M in its Series A round announced in April 2026.

Participated · Series C · Jan 2026

Soley Therapeutics leverages live human cells as biosensors, capturing thousands of time-resolved features and translating them with proprietary computer vision and AI into structured signatures that reveal novel druggable biology. Its fully automated, high-throughput platform can screen hundreds of thousands of compounds per week, accelerating hit identification, mechanistic insight, and molecule design. The company’s lead oncology program targets acute myeloid leukemia and is slated for an IND filing in 2026, while a second solid-tumor asset is entering IND-enabling studies. Beyond oncology, Soley is advancing stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases. Recent funding will also support continued scale-up of the platform, which combines Oracle Cloud Infrastructure, NVIDIA AI Enterprise, and NVIDIA Blackwell GPUs. Headquartered in South San Francisco, Soley positions itself as a science-first organization marrying foundational biology with state-of-the-art automation and AI to build a broad, first-in-class pipeline.